The Watson-powered Pathway Panorama mobile app will be able to answer wellness related questions based on user’s genetics and devices
NEW YORK & SAN DIEGO, CA – 12 Nov 2014: Cognitive apps are in market today and continue to change the way professionals and consumers make decisions. To help accelerate this transformation, the IBM Watson Group (NYSE: IBM) announced an investment in Pathway Genomics Corporation, a clinical laboratory that offers genetic testing services globally, to help deliver the first-ever cognitive consumer-facing app based on genetics from a user’s personal makeup.
Pathway Genomics announced that world-renowned endocrinologist Dr. Glenn D. Braunstein has joined Pathway Genomics’ medical advisory board. Dr. Braunstein is currently the vice president of clinical innovation, director of the Thyroid Cancer Center and professor of medicine at Cedars-Sinai. For 26 years he served as chair of the Department of Medicine at Cedars-Sinai, and holds the James R. Klinenberg, M.D., Chair in Medicine.
“We are honored to have Dr. Braunstein on our medical advisory board, and we look forward to his expert contributions as we rapidly grow our commercial and research divisions,” said Jim Plante, Pathway Genomics’ founder and CEO. “His vast knowledge and veteran experience in medicine will help us continue to enhance and deliver clinically useful genetic tests to physicians and patients.”
Pathway Genomics announced that its breast cancer risk genetic test, BRCATrue, was included in Inc. magazine’s Coolest Products of the Inc. 500. The genetic test was ranked in the top 12 products from 5000 companies across the nation. View the full list here.
“We are honored to be included among incredibly innovative products and forward-thinking companies,” said Jim Plante, Pathway Genomics’ founder and CEO. “Our mission is to provide the most accurate and actionable genetic testing results to physicians and their patients.”
SAN DIEGO, CA – October 20, 2014 – Pathway Genomics Corporation, a CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced it has released a patient app that allows existing patients to view their genetic results on mobile devices, such as smart phones and tablets. The announcement was made at the 64th Annual Meeting of the American Society of Human Genetics (ASHG) in San Diego, California.
“Pathway’s patient app empowers the individual to view their genetic testing results with a push of a button from their mobile device,” said Jim Plante, Pathway Genomics’ founder and CEO. “Patients can now have their genetic testing results accessible at all times.”
SAN DIEGO, CA –September 18, 2014 – Pathway Genomics Corporation, a global clinical genetic testing company, announced today at the National Society of Genetic Counselors’ 33rd Annual Education Conference its commitment to Free the Data, a movement dedicated to open access to genetic data and collaboration through information sharing.
SAN DIEGO, CA – September 10. 2014 – Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, today announced it has launched BreastTrueTM High Risk Panel, a next-generation sequencing test with deletion/duplication analysis to detect mutations in seven high-risk breast cancer susceptibility genes, including BRCA1, BRCA2 and PALB2.
September 9, 2014 | Susan G. Komen, the world’s largest breast cancer organization, issued a press release this morning announcing a national partnership agreement with global clinical laboratory Pathway Genomics to fund community breast cancer education and outreach programs in five cities nationwide.
The partnership includes funding for education programs and/or sponsorship of Susan G. Komen Race for the Cure® events in San Diego, Los Angeles, Denver and Seattle, along with funding for grants to reach medically underserved women in Washington, D.C., which has the highest death rate from breast cancer of any city in the United States.
SAN DIEGO, CA – August 20, 2014 – Inc. magazine today ranked global genetic testing company Pathway Genomics No. 173, with a three-year growth rate of 2,415.5%, on its 33rd annual Inc. 500|5000, an exclusive ranking of the nation’s fastest-growing private companies. The list represents the most comprehensive look at the most important segment of the economy — America’s independent entrepreneurs. Companies such as Yelp, Pandora, Timberland, Dell, Domino’s Pizza, LinkedIn, Zillow, and many other well-known names gained early exposure as members of the Inc. 500|5000.
SAN DIEGO, CA – August 5, 2014 – Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced its laboratory director, Dr. Linda Wasserman, was an honorary speaker at the second annual National Women’s Survivors Convention. Held last week in Nashville, Tennessee, the convention serves as a place for women survivors of cancer to come together over issues surrounding survivorship. The purpose of the convention is to help women re-enter their lives by supporting, educating, and connecting them with other women whose lives have been touched by cancer. This year’s convention hosted more than 800 people affected by cancer.
Embrey brings extensive executive health and medical experience in federal service as well as military and veteran affairs issues to the board
SAN DIEGO, CA – July 10, 2014 – Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced that Ellen Embrey, B.S., has joined its strategic advisory board. Embrey earned a bachelor’s degree from Virginia Tech and was twice awarded the Department of Defense (DOD) Distinguished Civilian Service Award. Embrey brings extensive executive health and medical experience in federal service as well as military and veteran affairs issues to the board.